Clinical Trial Update: A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for IBI362 in Chinese adults with obstructive sleep apnea and obesity (BMI ≥ 28 kg/m2), currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Obstructive Sleep Apnea

Drugs mentioned

• IBI362

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Sleep Apnea, Obstructive | Phase 3 | Status: RECRUITING